Novo Nordisk A/S (NVON)

2,080.430
+2.100(+0.10%)
  • Volume:
    151
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    2,080.430 - 2,080.430
  • Type:Equity
  • Market:Mexico
  • ISIN:US6701002056

NVON Overview

Prev. Close
2,078.33
Day's Range
2,080.43-2,080.43
Revenue
-
Open
2,080.43
52 wk Range
1,315.43-2,184.42
EPS
-
Volume
151
Market Cap
4.77T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
621
P/E Ratio
-
Beta
-
1-Year Change
36.02%
Shares Outstanding
2,288,634,053
Next Earnings Date
-
What is your sentiment on Novo Nordisk A/S?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S News

Novo Nordisk A/S Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryBuyStrong BuyStrong BuyStrong BuyStrong Buy

Novo Nordisk A/S Company Profile

Novo Nordisk A/S Company Profile

Employees
45971

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Read More
  • Name a better company
    0
    • Great company
      0
      • NVO WILL BUY ORMP AT 30 $
        0
        • and Gals..! :D
          0
          • Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
            1
            • Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
              0
          • Very good long term investment
            0
            • Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
              0
              • My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.